ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Oxymetazoline

Also written as “OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)”, “Oxymetazoline Hydrochloride” and “Oxymetazoline HCL Cream 1.0%”.

Its studies are mostly in Rosacea · Erythema · Fecal Incontinence · Rhinitis, Allergic · Nasal Obstruction, led by 10 companies.

Drug pageOxymetazoline: every studyMany companies study it; this page follows only the 16 they lead. All 44 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 21, 201416 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie60 open or runningphase 3since Mar 21, 2014Apr 13, 2012none ahead
RDD Pharmaits history only20 open or runningphase 2since Nov 17, 2014Nov 17, 2014none ahead
Aclaris Therapeuticsits history only10 open or runningphase 4since Dec 18, 2017Dec 18, 2017none ahead
Bayerits history only10 open or runningphase 2since May 6, 2026May 6, 2026none ahead
Eye Therapiesits history only10 open or runningphase 2since Jan 10, 2011Jan 10, 2011none ahead
Johnson & Johnsonits history only10 open or runningphase 1since May 30, 2014May 30, 2014none ahead
Padagisits history only10 open or runningphase 3since Nov 7, 2017Nov 7, 2017none ahead
Santen Pharmaceuticalits history only11 open or runningphase 3since Jul 3, 2024Jul 3, 2024none ahead
Sun Pharmaceutical Industriesits history only10 open or runningphase 1since Nov 23, 2021Nov 23, 2021none ahead
Teva Pharmaceutical Industriesits history only10 open or runningphase 3since Apr 10, 2019Apr 10, 2019none ahead

Also a collaborator on its studies: Quintiles, Ground Zero Pharmaceuticals, Rho and ORA.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 13, 2012First study: phase 1 study in RosaceaFirst studyNCT01579084 · 64 enrolled · United States
  2. Nov 26, 2012Phase 2 study in RosaceaNCT01735201 · 357 enrolled · United States
  3. Mar 21, 2014Phase 3 study in ErythemaNCT02095158 · 440 enrolled · United States
  4. May 5, 20142 phase 3 studies in ErythemaNCT02132117, NCT02131636
  5. Jul 21, 2014Phase 2 study in PresbyopiaNCT02197806 · 65 enrolled · United States

TargetBeta

“Adrenergic receptor alpha agonist”ChEMBL 37, by rule

Other programs on the same 6 targets

ProgramCompanyFurthest phaseStudies
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417

Studies

All 6 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02197806Presbyopia · United States2CompletedOct 201465
NCT02132117Erythema · United States3CompletedApr 2015445
NCT02131636Erythema · United States3CompletedNov 2014440
NCT02095158Erythema · United States3CompletedAug 2015440
NCT01735201Rosacea · United States2CompletedMay 2013357
NCT01579084Rosacea · United States1CompletedJun 201264

How it is read

Names in the registry

  • “Oxymetazoline”, 3 entries
  • “OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)”, 2 entries
  • “Oxymetazoline Hydrochloride”, 2 entries
  • “Oxymetazoline HCL Cream 1.0%”, 2 entries
  • “AGN-199201”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.